AnaptysBio ANAB

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.03 (-0.18%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AnaptysBio (ANAB)
    AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $16.34

    • Market Cap

      $501.10 Million

    • Price-Earnings Ratio

      -2.70

    • Total Outstanding Shares

      30.67 Million Shares

    • Total Employees

      136

    • Dividend

      No dividend

    • IPO Date

      January 26, 2017

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      10770 wateridge circle, suite 210, San diego, CA, 92121

    • Homepage

      https://www.anaptysbio.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow$165.29 Million
    Net Cash Flow From Financing Activities, Continuing$94.33 Million
    Net Cash Flow, Continuing$165.29 Million
    Net Cash Flow From Operating Activities$-103.01 Million
    Net Cash Flow From Financing Activities$94.33 Million
    Net Cash Flow From Operating Activities, Continuing$-103.01 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Basic Earnings Per Share$-6.05
    Basic Average Shares$27.57 Million
    Diluted Average Shares$27.57 Million
    Preferred Stock Dividends And Other Adjustments$0
    Net Income/Loss Available To Common Stockholders, Basic$-165.66 Million
    Revenues$57.17 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$-162.55 Million
    Comprehensive Income/Loss$-162.55 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss Attributable To Parent$3.11 Million
    Comprehensive Income/Loss Attributable To Parent$-162.55 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity Attributable To Noncontrolling Interest$0
    Equity Attributable To Parent$84.37 Million
    Other Current Liabilities$32.38 Million
    Liabilities And Equity$493.42 Million
    Other Current Assets$436.49 Million
    Current Liabilities$43.88 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ANAB from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.